glp 1 compound fda Ends Compounded GLP-1s: What to Know Novo asks FDA to prevent

doi: 10.3390/ijms20194881 157 SchimmeyerJ.BockR.MeyerE

Oral formulations are essentially biologically inert at standard supplement doses

Indication Pediatric Patients ZOMACTON is indicated for the treatment of Pediatric patients with: Growth Failure due to Inadequate secretion of Endogenous growth hormone (GH), Short stature Associated with Turner syndrome, Idiopathic Short Stature (ISS), height Standard Deviation score (HSDS) -2.25 and associated with growth rates unlikely to permit Attainment of adult height in the normal range, Concerning Short Stature or growth Failure in short Stature home box-containing gene (SHOX) Deficiency, Below Short Stature born small for Gestational age (SGA) with no catch-up growth by 2 years to 4 years of age

Zahreddine H, Borden KLB